Randomized Trialhigh evidence
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine·May 13, 2026·PMID 42120723
Why it mattersOrforglipron is a once-daily oral nonpeptide GLP-1 agonist, offering a potentially more convenient and scalable alternative to injectable therapies for long-term weight maintenance. This trial provides evidence that transitioning from injectable to oral therapy can sustain meaningful weight loss, which may improve adherence and access.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled